ACADIA Pharma (ACAD): EV/EBITDA Multiple
ACADIA Pharmaceuticals dominates the rare brain pathology niche thanks to patents on unique molecules. The EV/EBITDA valuation multiple reflects market expectations, where 16.62 is established as the baseline value. Growth is driven by therapies for Parkinson's disease psychosis and Rett syndrome. Stability is underpinned by a secure cash flow, despite the reliance on key drugs.
Comprehensive metric breakdowns and analytics for acadia-pharm.com (ACAD)
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ACADIA Pharmaceuticals Inc.|ACAD - Company Aggregate Indebtedness|Debts to Book Capitalization ACADIA Corp|ACAD - Company Long-Term Loans and Borrowings|Company Short-Term Debts ACADIA Pharmaceuticals|Quick Liquidity acadia-pharm.com
- financial results and valuation multiples details:
ACAD - Final Profit|Expected Profit ACADIA Pharmaceuticals|ACAD - Price to Earnings Ratio|Forward P/E Multiple ACADIA Pharmaceuticals|ACAD - PEG Multiple|EV/EBITDA Multiple ACADIA Corp|ACAD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) ACADIA Pharmaceuticals|ACAD - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months acadia-pharm.com|ACAD - Earnings growth in current year|Expected earnings per share growth for next year ACADIA Pharmaceuticals
Fundamental valuation:ACADIA Pharmaceuticals Inc ACAD
For long-term asset screening, analyzing business value relative to operational efficiency is critical. The enterprise value to EBITDA ratio for ACADIA Pharmaceuticals (ACAD), which stands at 16.62, allows for a valuation that accounts for debt; given stable patent protection in the US, this minimizes risks and reflects the real-time dynamics in the history of the EV/EBITDA multiple.
Key competitors
EV/EBITDA Multiple BIIB (Biogen Corp)|EV/EBITDA Multiple Neurocrine Corp NBIX|Regencell Bioscience - EV/EBITDA Multiple|AXSM (axsome.com) - Enterprise Value to Operating Income Before Depreciation|XENE: EV/EBITDA Multiple|VKTX - Total Company Value to Operating Income Before Depreciation Ratio|SUPN (Supernus Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Catalyst Corp|Enterprise Value to EBITDA Ratio DNLI (Denali Therapeutics)|HRMY (harmonybiosciences.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biohaven BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Trevi Pharma - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|AVXL: EV/EBITDA Multiple|ceribell.com (CBLL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prothena Corporation plc|ALEC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Annexon Inc. (ANNX)|Enterprise Value to EBITDA Ratio omeros.com OMER|EV/EBITDA Multiple NGNE (Neurogene Inc.)|EV/EBITDA Multiple acimmune.com ACIU|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Neumora (NMRA) - Enterprise Value to EBITDA Ratio|SCLX: EV/EBITDA Multiple|Company Value to EBITDA Tevogen Bio Inc. (TVGN)|Enterprise Value to EBITDA Ratio ACOG|EV/EBITDA Multiple cogrx.com|Enterprise Value to EBITDA Ratio IKT (Inhibikase Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio SAVA|EV/EBITDA Multiple ASRT (Assertio)|Total Company Value to Operating Income Before Depreciation Ratio Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Ovid Therapeutics Inc. (OVID) - Enterprise Value to EBITDA Ratio|ABOS: EV/EBITDA Multiple|CervoMed, Inc. (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|EV/EBITDA Multiple Annovis Bio Inc ANVS|Grace Tx - EV/EBITDA Multiple|Firefly Neuro (AIFF) - Enterprise Value to EBITDA Ratio|KLTO: EV/EBITDA Multiple|NeuroSense Therapeutics Ltd. (NRSN) - EV/EBITDA Multiple|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MTVA (MetaVia, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|heliusmedical.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|NERV: Enterprise Value to EBITDA Ratio|ATHA - EV/EBITDA Multiple|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Alzamend Neuro - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Company Value to EBITDA Protagenic PTIX|EV/EBITDA Multiple KTTA|EV/EBITDA Multiple cortigent.com (CRGT)|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|BCLI - Enterprise Value to EBITDA Ratio|Cara Therapeutics, Inc. - EV/EBITDA Multiple|CHRO - EV/EBITDA Multiple|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Marinus Pharma (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|cerevel.com - Business Value to Operating Income Before Depreciation
